Anemia is defined as a low concentration of blood hemoglobin. It is a health problem that affects all economical sections of world ranging from low-, middle- and high-income countries. significant adverse health consequences of anemia along with worse impacts on economic and social development.
Anemia occurs due to various etiologies, with the most common contributor is iron deficiency. Approximately 50% of cases of anemia cases are caused due to iron deficiency, but the ratio probably varies due to various factors.
Other causes of anemia include other deficiencies of micronutrient (e.g. vitamins A, folate, riboflavin and B12), chronic and acute infections (e.g. cancer, tuberculosis, malaria, and HIV), and acquired or inherited disorders that affect synthesis of hemoglobin, red blood cell (RBC) production or survival.
Iron deficiency anemia is said to be the most common form of anemia found globally. In this condition blood lacks sufficient healthy red blood cells (RBC’s) which functions to carry oxygen to the tissue of the body’s Iron deficiency anemia is caused due to insufficient iron.
The lack of proper nutrition and various inflammations in body which renders the poor absorption of the iron leads to increased prevalence of iron deficiency anemia.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-iron-deficiency-anemia-therapy-market
Data Bridge Market Research analyzes that the Global Iron-Deficiency Anemia Therapy Market is expected to reach USD 10.08 billion by 2031 from USD 4.86 billion in 2023, growing with a CAGR of 10.0% in the forecast period of 2024 to 2031.
Key Findings of the Study
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Year
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Therapy (Parenteral Iron Therapy and Oral Iron Therapy), Therapy Area (Obstetrics and Gynecology, Renal Diseases, Congestive Heart Failure (CHF), Oncology, Inflammatory Bowel Disease, and Others), Population (Adults, Geriatric, and Pediatric), End User (Hospitals, Specialty Clinics, Home Care Setting, and Others), Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacies, and Online Pharmacies)
|
|
Countries Covered
|
Mexico, Canada, U.S., U.K., Germany, Italy, France, Spain, Belgium, Switzerland, Turkey, Russia, Netherlands, Rest of Europe, India, China, Japan, Australia, Thailand, Malaysia, South Korea, Philippines, Singapore, Indonesia, Rest of Asia-Pacific, Argentina, Brazil, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Vifor Pharma Ltd. (Switzerland), DAIICHO SANKYO COMPANY LIMITED (Japan), AFT Pharmaceuticals. (New Zealand), Sanofi (France), Pfizer Inc. (U.S.), Akebia Therapautics Inc. (U.S.), Alkem. (India), Aspen Pharmacare Australia Pty Ltd. (Australia), Blackmores (Australia), Farlex (India), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The global iron-deficiency anemia therapy market is segmented into five notable segments based on therapy, therapy area, population, end user, and distribution channel.
- On the basis of therapy, the market is segmented into parenteral iron therapy, and oral iron therapy
In 2024, the parenteral iron therapy segment is expected to dominate the global iron-deficiency anemia therapy market
In 2024, the parenteral iron therapy segment is expected to dominate the market with a market share of 57.83% due to the increasing preference of parenteral.
- On the basis of therapy area, the market is segmented into obstetrics and gynecology, renal diseases, Congestive Heart Failure (CHF), oncology, inflammatory bowel disease, others
In 2024, the obstetrics and gynecology segment is expected to dominate the global iron-deficiency anemia therapy market
In 2024, the obstetrics and gynecology segment is expected to dominate the market with a market share of 37.97% due to the increasing prevalence of obstetrics and gynecology issues.
- On the basis of popultaion, the market is segmented into adults, geriatric, pediatric. In 2024, adults segment dominate the market with a market share of 42.50%
- On the basis of end user, the market is segmented into hospital, specialty clinics, home care setting, and others. In 2024, hospital segment dominate the market with a market share of 57.26%
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and online sales. In 2024, direct tender segment dominate the market with a market share of 56.46%
Major Players
Data Bridge Market Research analyzes Vifor Pharma Ltd. (Switzerland), DAIICHO SANKYO COMPANY LIMITED (Japan), AFT Pharmaceuticals. (New Zealand), Sanofi (France), Pfizer Inc. (U.S.), as the major companies operating in the global iron-deficiency anemia therapy market.
Market Developments
- In June 2023, GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending the authorization of daprodustat for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults undergoing chronic maintenance dialysis. This recommendation marks a significant step towards providing a new therapeutic option for managing anemia in CKD patients on long-term dialysis, addressing an important unmet medical need in this population
- In March 2024, Vafseo approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients. CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia
- In February 2024, Lupin launched a Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device), after having received an approval from the United States Food and Drug Administration (U.S. FDA)
- In December 2023, Novartis receives FDA approval for Fabhalta (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta (iptacopan) as the first oral monotherapy for the treatment of adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
- In March 2024, Ferinject approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure
Country Analysis
Geographically, the countries covered in the global iron-deficiency anemia therapy market report Mexico, Canada, U.S., U.K., Germany, Italy, France, Spain, Belgium, Switzerland, Turkey, Russia, Netherlands, rest of Europe, India, China, Japan, Australia, Thailand, Malaysia, South Korea, Philippines, Singapore, Indonesia, rest of Asia-Pacific, Argentina, Brazil, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America is expected to dominate the global iron-deficiency anemia therapy market
North America is expected to dominate the iron-deficiency anemia therapy market owing to the rising healthcare expenditure.
Asia-Pacific is expected to be the fastest growing region in the global iron-deficiency anemia therapy market
Asia-Pacific is expected to be the fastest growing country because of its growing healthcare infrastructure.
For more detailed information about the global iron-deficiency anemia therapy market report, click here – https://www.databridgemarketresearch.com/reports/global-iron-deficiency-anemia-therapy-market
